12:00 AM
 | 
Mar 12, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

DegludecPlus insulin degludec/insulin aspart regulatory update

Novo Nordisk submitted an NDA in Japan for DegludecPlus insulin degludec/insulin aspart to treat Type I and II diabetes. The product is also under review in...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >